Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medivir ABSTU:MVR0 -1.28%30 FCF Margin % is -1,297.85% as of Mar. 2026. GuruFocus rates STU:MVR0 with a GF Score™ of 30/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 953 Biotechnology companies, Medivir AB ranks worse than 75.97% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Medivir AB's Free Cash Flow for the
three
months ended in Mar. 2026 was €-1.21 Mil. Medivir AB's Revenue for the
three
months ended in Mar. 2026 was €0.09 Mil. Therefore, Medivir AB's FCF Margin % for the quarter that ended in Mar. 2026 was -1,297.85%.
The historical data trend for Medivir AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MVR0 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Medivir AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Medivir AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (STU:MVR0) has a FCF Margin % of -1,297.85% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medivir AB and its competitors. According to the industry distribution chart, Medivir AB ranks #724 out of 953 companies in the Biotechnology industry, placing it in the top 76%.
Is Medivir AB's FCF Margin % too high?
Medivir AB's current FCF Margin % is -1,297.85%. Based on the distribution chart, Medivir AB ranks #724 out of 953 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medivir AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #724 out of 953 companies for FCF Margin %. This places Medivir AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medivir AB and its competitors. Medivir AB's current FCF Margin % is -1,297.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (STU:MVR0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.15 — trading 71.3% above its estimated fair value. The current FCF Margin % is -1,297.85%. Medivir AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medivir AB (STU:MVR0), the current FCF Margin % is -1,297.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (STU:MVR0) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of €0.15 is trading 71.3% above its estimated GF Value™ of €0.09.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for STU:MVR0:
FCF Margin %: -1,297.85%
GF Value™: €0.09 vs. price of €0.15 (71.3% above fair value)
No single metric tells the full story. See the STU:MVR0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
30GF Score
Get the complete analysis for STU:MVR0
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MVR0 has been successfully added to your 
